JP7834754B2 - 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物 - Google Patents

重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物

Info

Publication number
JP7834754B2
JP7834754B2 JP2023533243A JP2023533243A JP7834754B2 JP 7834754 B2 JP7834754 B2 JP 7834754B2 JP 2023533243 A JP2023533243 A JP 2023533243A JP 2023533243 A JP2023533243 A JP 2023533243A JP 7834754 B2 JP7834754 B2 JP 7834754B2
Authority
JP
Japan
Prior art keywords
compound
formula
disorder
compounds
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023533243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551058A (ja
JP2023551058A5 (https=
Inventor
ランズ，ピーター
ジェイムズ，エレン
ベンウェイ，ティファニー
ジョエル，ゼラ
レイゼル，マリー
Original Assignee
サイビン ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/en
Priority claimed from US17/320,155 external-priority patent/US12042564B2/en
Application filed by サイビン ユーケー リミテッド filed Critical サイビン ユーケー リミテッド
Publication of JP2023551058A publication Critical patent/JP2023551058A/ja
Publication of JP2023551058A5 publication Critical patent/JP2023551058A5/ja
Publication of JP7834754B2 publication Critical patent/JP7834754B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023533243A 2020-12-01 2021-11-18 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物 Active JP7834754B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GB2018955.1 2020-12-01
US17/108,938 2020-12-01
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3 2021-03-22
US17/208,583 2021-03-22
EPPCT/EP2021/060750 2021-04-23
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
GB2106881.2 2021-05-13
CA3118556A CA3118556A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
EPPCT/EP2021/062794 2021-05-13
US17/320,155 US12042564B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
CA3118556 2021-05-13
GB2106881.2A GB2595776B (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/320,155 2021-05-13
PCT/EP2021/082227 WO2022117359A1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds

Publications (3)

Publication Number Publication Date
JP2023551058A JP2023551058A (ja) 2023-12-06
JP2023551058A5 JP2023551058A5 (https=) 2024-11-08
JP7834754B2 true JP7834754B2 (ja) 2026-03-24

Family

ID=88294961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533243A Active JP7834754B2 (ja) 2020-12-01 2021-11-18 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物

Country Status (8)

Country Link
EP (2) EP4031529B1 (https=)
JP (1) JP7834754B2 (https=)
CN (1) CN116761599B (https=)
AU (1) AU2021391581A1 (https=)
CA (1) CA3203020A1 (https=)
IL (1) IL303288A (https=)
TW (1) TWI891942B (https=)
WO (1) WO2022117359A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4433049A1 (en) * 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
EP4463440A1 (en) * 2022-01-14 2024-11-20 Cybin IRL Limited Tryptamine compositions and methods
US12264131B2 (en) * 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
AU2023361184A1 (en) 2022-10-13 2025-04-24 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
CN121038789A (zh) 2023-01-23 2025-11-28 赛本英国有限公司 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍
CN121194779A (zh) 2023-03-31 2025-12-23 赛本英国有限公司 包含单胺抗抑郁剂和短效致幻剂的组合
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
KR20220137081A (ko) * 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
MX2022014900A (es) * 2020-06-02 2023-03-27 Small Pharma Ltd Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Labelled Compounds and Radiopharmaceuticals，1993年，Vol.33, No.6，pp.455-465
Pharmacology & Therapeutics，2004年，Vol.101，pp.131-143, 162-168
佐藤 健太郎，広がる重水素の用途，Wako Organic Square，No.33，2010年，pp.1-3

Also Published As

Publication number Publication date
CN116761599A (zh) 2023-09-15
WO2022117359A1 (en) 2022-06-09
CA3203020A1 (en) 2022-06-09
IL303288A (en) 2023-07-01
EP4275753B1 (en) 2026-03-18
CN116761599B (zh) 2025-05-30
EP4031529A1 (en) 2022-07-27
JP2023551058A (ja) 2023-12-06
EP4275753A2 (en) 2023-11-15
EP4031529C0 (en) 2023-09-27
EP4275753A3 (en) 2023-12-27
AU2021391581A1 (en) 2023-07-06
EP4031529B1 (en) 2023-09-27
TW202237565A (zh) 2022-10-01
TWI891942B (zh) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7834754B2 (ja) 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物
US12251371B2 (en) Deuterated or partially deuterated N,N-dimethyltryptamine compounds
ES2920681T3 (es) Compuestos
US11773062B2 (en) Deuterated compounds
US12521370B2 (en) Inhalable formulations
EP4255421A1 (en) Inhalable formulations
US20220169606A1 (en) Compositions and compounds for bioanalysis
CN116056763B (zh) 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物
HK40103232A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40078818B (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40078818A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
GB2605144A (en) Deuterated compounds
HK40060666B (en) Method of synthesis
HK40060666A (en) Method of synthesis
HK40056359B (en) Compounds
HK40056359A (en) Compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260311

R150 Certificate of patent or registration of utility model

Ref document number: 7834754

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150